Introduction
Longevity increase is an important part of economic growth and development. Nordhaus (2002) estimated that, "to a first approximation, the economic value of increases in longevity over the twentieth century is about as large as the value of measured growth in non-health goods and services" (p. 17). Murphy and Topel (2005) observed that "the historical gains from increased longevity have been enormous. Over the 20th century, cumulative gains in [U.S.] life expectancy were worth over $1.2 million per person for both men and women. Between 1970 and 2000 increased longevity added about $3.2 trillion per year to national wealth, an uncounted value equal to about half of average annual GDP over the period." In its Human Development Reports, the United Nations Development Program ranks countries by their value of the Human Development Index, which is based on life expectancy at birth as well as on the adult literacy rate and per capita GDP.
Since the 1950s, economists have recognized that, in the long run, the rate of economic growth is determined by (indeed equal to) the rate of technological progress. In neoclassical growth models developed by Robert Solow (1956 Solow ( , 1957 and colleagues, an economy will always converge towards a steady state rate of growth, which depends only on the rate of technological progress.
In early models of economic growth, the rate of technological progress was assumed to be given, or exogenous: technological progress was regarded as "manna from heaven."
Economists began to relax this clearly unrealistic assumption in the 1980s, by developing socalled "endogenous growth models." In Paul Romer's (1990) model, "growth…is driven by technological change that arises from intentional [R&D] investment decisions made by profitmaximizing agents." 1 Jones (1998) argues that "technological progress [is] the ultimate driving force behind sustained economic growth" (p.2), and that "technological progress is driven by research and development (R&D) in the advanced world" (p. 89).
Technological change may be either disembodied or embodied. Suppose firm X invests in R&D, and that this investment results in a valuable discovery. If the technological advance is disembodied, consumers and other firms could benefit from the discovery without purchasing firm X's goods or services; they could benefit just by reading or hearing about the discovery.
However, if the technological advance is embodied, consumers and other firms must purchase firm X's goods or services to benefit from its discovery. Solow (1960, p 91) : argued that "many if not most innovations need to be embodied in new kinds of durable equipment before they can be made effective. Improvements in technology affect output only to the extent that they are carried into practice either by net capital formation or by the replacement of old-fashioned equipment by the latest models…" 2 Romer also assumed that technological progress is embodied in new goods: "new knowledge is translated into goods with practical value," and "a firm incurs fixed design or research and development costs when it creates a new good. It recovers those costs by selling the new good for a price that is higher than its constant cost of production." Grossman and Helpman (1993) argued that "innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production." Bresnahan and Gordon (1996) stated simply that "new goods are at the heart of economic progress, " and Bils (2004) said that "much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models."
When technological progress is embodied in new goods, the welfare of consumers (and the productivity of producers) depends on the vintage of the goods (or inputs) they purchase. In this context, "vintage" refers to the year in which the good was first produced or sold. For example, the vintage of the drug simvastatin is 1993: that is the year it was approved by the FDA, and first sold. Solow was the first economist to develop a growth model that distinguished between vintages of (capital) goods. In Solow's model, new capital is more valuable than old capital because--since capital is produced based on known technology, and technology improves with time--new capital will be more productive than old capital. 3 A number of econometric studies (Bahk and Gort (1993) , Hulten (1992) , Sakellaris and Wilson (2004) ) have shown that manufacturing firms using later-vintage equipment have higher productivity.
The extent to which the welfare of consumers or the productivity of producers depends on the vintage of the goods they purchase should depend on the research intensity of those goods. The greater the research intensity of the goods, the greater the impact of their vintage on consumer welfare and producer productivity. According to the National Science Foundation, the pharmaceutical and medical devices industries are the most research intensive industries in the economy. 4 In this paper, I will analyze the effects of technological change embodied in diagnostic imaging equipment and pharmaceuticals on cancer mortality rates since the early to mid 1990s.
The analysis will be performed using aggregate data, as opposed to patient-level data. Grunfeld and Griliches (1960, p. 1) showed that "aggregation of economic variables can, and in fact frequently does, reduce…specification errors. Hence, aggregation does not only produce an aggregation error, but may also produce an aggregation gain." In particular, patient-level data are surely more subject to selection effects (the sickest patients might get the newest-or oldest-treatments) than aggregate data.
Two types of statistics are often used to assess progress in the "war on cancer": survival rates and mortality rates. Survival rates are typically expressed as the proportion of patients alive at some point subsequent to the diagnosis of their cancer. For example, the observed 5-year survival rate is defined as follows:
5-year Survival Rate = Number of people diagnosed with cancer at time t alive at time t+5 / Number of people diagnosed with cancer at time t = 1 -(Number of people diagnosed with cancer at time t dead at time t+5 / Number of people diagnosed with cancer at time t) Hence, the survival rate is based on a conditional (upon previous diagnosis) mortality rate. The second type of statistic is the unconditional cancer mortality rate: the number of deaths, with cancer as the underlying cause of death, occurring during a year per 100,000 population.
As shown in Figure 1a , the 5-year relative survival rate from cancer has increased steadily since the mid 1970s.
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Although this increase suggests that there has been significant 4 In 1997, "medical substances and devices firms had by far the highest combined R&D intensity at 11.8 percent,…well above the 4.2-percent average for all 500 top 1997 R&D spenders combined. The information and electronics sector ranked second in intensity at 7.0 percent." The pattern of 1997 R&D spending per employee is similar to that for R&D intensity, with medical substances and devices again the highest at $29,095 per employee. Information and electronics is second at $16,381. Combined, the top 500 1997 R&D firms spent $10,457 per employee. 5 Relative survival is defined as the ratio of the proportion of observed survivors (all causes of death) in a cohort of cancer patients to the proportion of expected survivors in a comparable cohort of cancer-free individuals. The formulation is based on the assumption of independent competing causes of death. Since a cohort of cancer-free individuals is difficult to obtain, we use expected life tables and assume that the cancer deaths are a negligible proportion of all deaths. Ederer et al (1961). progress in the war against cancer, it might simply be a reflection of (increasing) lead-time bias.
Lead time bias is the bias that occurs when two tests for a disease are compared, and one test (the new, experimental one) diagnoses the disease earlier, but there is no effect on the outcome of the disease--it may appear that the test prolonged survival, when in fact it only resulted in earlier diagnosis when compared to traditional methods. 6 Welch et al (2000) argued that "while 5-year survival is a perfectly valid measure to compare cancer therapies in a randomized trial, comparisons of 5-year survival rates across time (or place) may be extremely misleading. If cancer patients in the past always had palpable tumors at the time of diagnosis while current cancer patients include those diagnosed with microscopic abnormalities, then 5-year survival would be expected to increase over time even if new screening and treatment strategies are ineffective. " Welch et al (2000) found no correlation across cancer sites between the long-run (40-year) change in the (conditional) survival rate and the unconditional mortality rate.
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They concluded from this that "improving 5-year survival over time…should not be taken as evidence of improved prevention, screening, or therapy," and "to avoid the problems introduced by changing patterns of diagnosis…progress against cancer [should] be assessed using populationbased mortality rates." Bailar and Gornik (1997) assessed overall progress against cancer in the United States from 1970 through 1994 by analyzing changes in (unconditional) age-adjusted cancer mortality rates. They concluded that "observed changes in mortality due to cancer primarily reflect changing incidence or early detection. The effect of new treatments for cancer on mortality has been largely disappointing." Bailar and Gornik's assessment may have been unduly pessimistic: as shown in Figures   1b and 1c , during the period 1973-1994, the age-adjusted mortality rate increased 6.4%, while the age-adjusted incidence rate increased 22.6%. Although part of the relatively rapid growth of measured cancer incidence may have been due to improved detection, an important part may have been rapid growth in true incidence, due to a decline in competing mortality risks, especially from cardiovascular disease. More people developed cancer because they had survived heart attacks.
In the early 1990s, there was a marked change in U.S. cancer mortality and incidence.
After rising steadily for 15 years, the age-adjusted mortality rate declined steadily, falling 17.2% between 1991 and 2006. During the same period, the age-adjusted incidence rate declined 9.7%. I will analyze the effects of two important types of medical innovation-diagnostic imaging innovation and pharmaceutical innovation-and cancer incidence rates on unconditional cancer mortality rates since the early to mid 1990s. As stated by the National Cancer Institute (2010) imaging, by itself, is not a treatment, but can help in making better decisions about treatments. The same imaging technique can help doctors find cancer, tell how far a cancer has spread, guide delivery of specific treatments, or find out if a treatment is working… Imaging can be used to make cancer treatments less invasive by narrowly focusing treatments on the tumors. For instance, ultrasound, MRI, or CT scans may be used to determine exact tumor locations so that therapy procedures can be focused on the tumor, minimizing damage to surrounding tissue… Imaging can be used to see if a previously treated cancer has returned or if the cancer is spreading to other locations.
Several previous studies have examined the overall impact of medical innovation on cancer mortality.
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These studies may have been subject to several limitations. First, the outcome measure in all of these studies was the cancer survival rate-the proportion of patients alive at some point subsequent to the diagnosis of their cancer-and this measure may be subject to leadtime bias. Second, only one kind of medical innovation-chemotherapy innovation-was usually analyzed, and this was usually measured by the number of drugs potentially available to cancer patients, rather than by the drugs actually used by them. This paper builds upon previous research in several ways. First, the outcome measure we use-the unconditional cancer mortality rate (the number of deaths, with cancer as the underlying cause of death, occurring during a year per 100,000 population)-is not subject to lead-time bias. Second, we analyze the effects of two important types of medical innovationdiagnostic imaging innovation and pharmaceutical innovation-and cancer incidence rates on cancer mortality rates. Third, our measures of medical innovation are based on extensive data on treatments given to large numbers of patients with different types of cancer.
8 Lichtenberg (2008 Lichtenberg ( , 2009a Lichtenberg ( , 2009b examined the effect of pharmaceutical innovation on relative cancer survival rates, controlling for variables likely to reflect changes in probability of diagnosis (e.g. age at diagnosis, cancer stage of diagnosis, and number of people diagnosed).
Methodology
The unconditional cancer mortality rate is essentially the unconditional probability of death from cancer (P(death from cancer)). The law of total probability implies the following: P(death from cancer) = P(death from cancer | cancer diagnosis) * P(cancer diagnosis) + P(death from cancer | no cancer diagnosis) * (1 -P( cancer diagnosis))
If the probability that a person who has never been diagnosed with cancer dies from cancer is quite small (P(death from cancer | no cancer diagnosis) ≈ 0), which seems plausible, 9 this reduces to P(death from cancer) ≈ P(death from cancer | cancer diagnosis) * P(cancer diagnosis) (2) Hence ln P(death from cancer) ≈ ln P(death from cancer | cancer diagnosis)
I hypothesize that the conditional mortality rate (P(death from cancer | cancer diagnosis)) depends upon the average quality of imaging and pharmaceutical procedures: 10 ln P(death from cancer | cancer diagnosis) =  1 image_quality +  2 drug_quality (4) Substituting (4) into (3), ln P(death from cancer) ≈  1 image_quality
I will estimate difference-in-difference (DD) versions of eq. (5) using longitudinal, cancer-site-level data on over 60 cancer sites.
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The equations will be of the following form:
9 The cancer incidence rate is 2.5 times as high as the cancer mortality rate: 2006 U.S. age-adjusted incidence and mortality rates were 456.2 and 181.1, respectively. Since the probability of dying from cancer is much lower than the probability of being diagnosed with cancer, P(death from cancer|no cancer diagnosis) is likely to be small. 10 The average quality of imaging procedures may also affect the probability of diagnosis. 11 The cancer sites are those included in the National Cancer Institute's SEER Cause of Death Recode shown in Appendix Table 1 .
where mort_rate st = the age-adjusted mortality rate from cancer at site s (s = 1,…, 60) in year t (t=1991,…,2006) adv_imag% s,t-k = advanced imaging procedures as % of total imaging procedures associated with cancer at site s in year t-k (k=0,1,…) new_drug% s,t-k = "new" (e.g. post-1990) drug procedures as % of all drug procedures associated with cancer at site s in year t-k (k=0,1,…) inc_rate s,t-k = the age-adjusted incidence rate of cancer at site s in year t-k  s = a fixed effect for cancer site s  t = a fixed effect for year t
If the replacement of standard imaging procedures by advanced imaging procedures has reduced the age-adjusted mortality rate, conditional on cancer drug innovation and cancer incidence, cancer sites that have had above-average increases in adv_imag% would have had above-average reductions in the age-adjusted mortality rate. This hypothesis may be tested by testing whether   < 0 in eq. (6). Similarly, if the replacement of old drug procedures by new drug procedures has reduced the age-adjusted mortality rate, conditional on diagnostic imaging innovation and cancer incidence, cancer sites that have had above-average increases in new_drug% would have had above-average reductions in the age-adjusted mortality rate. This hypothesis may be tested by testing whether   < 0 in eq. (6).
This equation will be estimated via weighted least-squares, weighting by the mean mortality rate of cancer site s during the entire sample period ((1 / T) ∑ t mort_rate st ). The estimation procedure will account for clustering of disturbances within cancer sites. Eq. (6) includes lagged values of adv_imag% and the other explanatory variables, since it may take several years for advanced imaging procedure utilization to have its peak effect on mortality rates.
The imaging procedure innovation measure will be constructed as follows:
where n_proc pst = the number of times diagnostic imaging procedure p was performed in connection with cancer diagnosed at site s in year t adv p = 1 if procedure p is an advanced imaging procedure = 0 if procedure p is a standard imaging procedure
The drug procedure innovation measure will be constructed as follows: 
Data and descriptive statistics
Cancer incidence and mortality rates. Data on age-adjusted cancer incidence and mortality rates, by cancer site and year, were obtained from the National Cancer Institute's Cancer Query Systems (http://seer.cancer.gov/canques/index.html). Mortality data are based on a complete census of death certificates and are therefore not subject to sampling error, although they are subject to other errors, i.e. errors in reporting cause of death and age at death.
14 Cancer incidence rates are based on data collected from population-based cancer registries, which 12 Drug procedures are procedures listed on MEDSTAT outpatient and inpatient claims with the following service types (STDSVC): chemotherapy (STDSVC=111), drugs (NEC) (STDSVC=155), or injectable medications (STDSVC=158). 13 I will define y in two different ways: y=1990 and y=1995. 14 During the period 1979-1998, cause of death was coded using ICD9 codes. Since 1999, cause of death has been coded using ICD10 codes. An advantage of the National Cancer Institute's Cancer Query Systems is that the mortality data from the two periods have been linked together.
currently cover approximately 26 percent of the US population; incidence rates are therefore subject to sampling error. Medicare is not covered.
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The majority of cancer patients are enrolled in Medicare. 
Empirical results
Estimates of the model of the age-adjusted mortality rate (eq. (6)) are presented in Table   2 . Since the mortality rate may depend on lagged as well as contemporaneous values of incidence and innovation, there are many possible specifications (corresponding to different lag structures) of eq. (6). To reduce the number of specifications, we will proceed as follows. First, we will analyze the effect of just one variable-incidence in year t-k-on mortality in year t, for different values of k. Next, we will analyze the effect of imaging innovation in year t-k on mortality in year t, for different values of k, conditional on the appropriate incidence lag and drug innovation in year t. Finally, we will analyze the effect of drug innovation (measured in two different ways) in year t-k on mortality in year t, for different values of k, conditional on the appropriate incidence and imaging innovation lags.
Models 1 through 9 are fixed-effect regressions of mortality in year t on incidence in year t-k (k = 0,1,…,8). The coefficients and 95% confidence limits from these models are plotted in Figure 6 . The coefficients of the first eight models are positive and significant at the 5% level.
The largest coefficient is for k = 5, suggesting that an increase in incidence has its largest impact on mortality with a five-year lag. 20 One might expect the number of post-1995 procedures to be zero before 1996. There may be a few errors in my procedure for determining the initial year of FDA approval of active ingredients. Also, patients may have access to investigational drugs prior to their approval by the FDA.
The fact that changes in incidence have a significant effect on mortality suggests that at least part of the changes in incidence are "real"; changes in measured incidence are not purely a result of changes in measurement or screening. Although the elasticity of mortality with respect to incidence is positive and significant, the largest estimate is substantially less than one: the coefficient on ln(inc_rate s,t-5 ) in model 6 is .351. This may be due to several factors: sampling error, changes in screening practices, and "learning by doing" or scale economies in cancer treatment: an increase in the number of patients with a given type of cancer may increase average treatment quality.
Models 10 through 15 explore the imaging innovation lag structure: they are regressions of ln(mort_rate st ) on adv_imag% s,t-k for different values of k (k= 0,1,…,5), controlling for new_drug% s,t and ln(inc_rate s,t-5 ). The imaging innovation coefficients and their 95% confidence limits are plotted (on an inverted scale) in Figure 7 . When k equals 0, 1, or 2, the imaging innovation coefficient is not statistically significant. However, when k equals 3, 4, or 5, the imaging innovation coefficient is negative and significant. This indicates that use of more advanced imaging procedures reduces cancer mortality rates 3-5 years later.
Models 16 through 18 explore the drug innovation lag structure, using one measure of drug innovation: drug treatments involving ingredients approved by the FDA after 1990 as a fraction of total drug treatments (post1990%). They are regressions of ln(mort_rate st ) on post1990% s,t-k for different values of k (k= 0,1,2), controlling for adv_imag% s,t-5 and ln(inc_rate s,t-5 ). The coefficient on the contemporaneous drug innovation measure (post1990% s,t ) in model 16 is negative and significant; the coefficients on lagged drug innovation in models 17
and 18 are not significant. This may be due, in part, to the fact that post1990% is likely to be a "lagging indicator" of the true increase in chemotherapy treatment vintage, due to delays in the establishment by CMS of procedure codes for new chemotherapy procedures. Also, the number of drug treatments early in the sample period was quite small.
Models 19 through 21 explore the drug innovation lag structure, using an alternative measure of drug innovation: drug treatments involving ingredients approved by the FDA after 1995 as a fraction of total drug treatments (post1995%). They are regressions of ln(mort_rate st ) on post1995% s,t-k for different values of k (k= 0,1,2), controlling for adv_imag% s,t-5 and ln(inc_rate s,t-5 ). Once again, the coefficient on the contemporaneous drug innovation measure (post1995% s,t ) in model 19 is negative and significant; the coefficients on lagged drug innovation in models 20 and 21 are not significant.
Models 16 and 19 both indicate that there is a significant inverse relationship between the age-adjusted cancer mortality rate and both lagged imaging innovation and contemporaneous drug innovation, and a significant positive relationship between the age-adjusted cancer mortality rate and the lagged incidence rate. While there is some correlation across cancer sites between changes in imaging innovation, drug innovation, and incidence, Table 3 shows that we obtain similar estimates of the effects of imaging and drug innovation on the cancer mortality rate, whether or not we control for the other factors.
During the sample period (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) , the age-adjusted cancer mortality rate declined 13.4%, from 207.0 to 181.1 deaths per 100,000 population. We can use our estimates to assess the contributions of imaging innovation, drug innovation, and declining cancer incidence to this decline in the cancer mortality rate. For example, the estimated contribution of imaging innovation is   (adv_imag% .,1991 -adv_imag% .,2001 ), where adv_imag% .,t is the (weighted) average value of adv_imag% across all cancer sites in year t. Using the estimates of   ,   , and   from model 16 in Table 2 , we obtain the following decomposition of the 1996-2006 decline in cancer mortality:
Factor Contribution to the 1996-2006 decline in the age-adjusted cancer mortality rate imaging innovation 5.3% drug innovation 3.7% decline in age-adjusted incidence 1.0% other factors 3.4% TOTAL 13.4%
Imaging innovation, drug innovation, and declining incidence jointly explain about three-fourths of the decline in cancer mortality. Only 7% of the mortality decline is attributable to the decline in (lagged) incidence. About one-fourth (27%) of the mortality decline is attributable to drug innovation, and 40% of the decline is attributable to (lagged) imaging innovation.
If we assume that the decline in cancer mortality had no effect on (did not increase) mortality from other causes of death, we can also estimate how much cancer imaging and drug innovation increased life expectancy at birth in the U.S. between 1996 and 2006. The calculations above imply that cancer imaging innovation and drug innovation reduced the cancer mortality rate by 10.2 (= 40% * 25.9) and 7.1 (= 27% * 25.9) deaths per 100,000 population, respectively. During this period, the age-adjusted mortality rate from all causes of death declined by 119.4 deaths per 100,000 population, from 894.5 to 775.1, and life expectancy at birth increased by 1.6 years, from 76.1 to 77.7 years.
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If the decline in cancer mortality had no effect on mortality from other causes of death, about 9% (= 10.2 / 119.4) of the decline in the mortality rate from all causes of death is attributable to cancer imaging innovation, and about 6% is attributable to cancer drug innovation. Life expectancy at birth may have been increased by just under three months (= (9% + 6%) * 1.6 years) between 1996 and 2006 by the combined effects of cancer imaging and cancer drug innovation. Research by Nordhaus (2003 ), Viscusi (2004 , and Murphy and Topel (2006) indicates that Americans place a high value on increased life expectancy.
Summary
Several previous studies have examined the overall impact of medical innovation on cancer mortality. These studies may have been subject to several limitations. First, the outcome measure in all of these studies was the cancer survival rate-the proportion of patients alive at some point subsequent to the diagnosis of their cancer-and this measure may be subject to leadtime bias. Second, only one kind of medical innovation-chemotherapy innovation-was usually analyzed, and this was usually measured by the number of drugs potentially available to cancer patients, rather than by the drugs actually used by them.
This paper builds upon previous research in several ways. First, the outcome measure we use-the unconditional cancer mortality rate (the number of deaths, with cancer as the underlying cause of death, occurring during a year per 100,000 population)-is not subject to lead-time bias. Second, we analyze the effects of two important types of medical innovationdiagnostic imaging innovation and pharmaceutical innovation-and cancer incidence rates on cancer mortality rates. Third, our measures of medical innovation are based on extensive data on treatments given to large numbers of patients with different types of cancer.
We estimated difference-in-difference models of the age-adjusted cancer mortality rate using longitudinal, annual, cancer-site-level data on over 60 cancer sites during the period 1996-
2006. There was a significant inverse relationship between the cancer mortality rate and both lagged imaging innovation and contemporaneous drug innovation, and a significant positive relationship between the cancer mortality rate and the lagged incidence rate. Imaging innovation, drug innovation, and declining incidence jointly explain about three-fourths of the decline in cancer mortality. Only 7% of the mortality decline is attributable to the decline in (lagged) incidence. About one-fourth (27%) of the mortality decline is attributable to drug innovation, and 40% of the decline is attributable to (lagged) imaging innovation. Our findings do not support the conclusions of a 1997 article assessing progress in the war on cancer:
"observed changes in mortality due to cancer primarily reflect changing incidence or early detection. The effect of new treatments for cancer on mortality has been largely disappointing."
Our findings also imply that the statement by Black and Welch (1993) that "the increasing use of sophisticated diagnostic imaging promotes a cycle of increasing intervention that often confers little or no benefit" does not apply to cancer. during the 1970s showed that chest X-rays, while they helped catch cancers at an earlier stage, had no effect on overall death rates.) The study involved more than 53,000 people ages 55 to 74 who had smoked at least 30 pack-years -one pack a day for 30 years or two packs a day for 15 years. Participants were followed for up to five years. The study found that for every 300 people who were screened, one person lived who would otherwise have died during the study.
An independent monitoring board determined that the benefits of CT scans were strong enough to stop the trial.
If the decline in cancer mortality had no effect on mortality from other causes of death, about 9% of the decline in the mortality rate from all causes of death is attributable to cancer imaging innovation, and about 6% is attributable to cancer drug innovation. Life expectancy at birth may have been increased by just under three months between 1996 and 2006 by the combined effects of cancer imaging and cancer drug innovation. 70% 1975-1977 1978-1980 1981-1983 1984-1986 1987-1989 1990-1992 1993-1995 1996-1998 1999-2005 Year of diagnosis 1b. Age-adjusted mortality rate (per 100,000 population) 80% 1991 1992 1993 1994 1995 1996 1997 1998 1999 40% 1992 1993 1994 1995 1996 1997 1998 1999 Incidence lag structure
Advanced imaging lag structure
Note: The dependent variable is ln(mort_rate st ). The equations were estimated via weighted least-squares, weighting by the mean mortality rate of cancer site s during the entire sample period ((1 / T) ∑ t mort_rate st ). The estimation procedure accounts for clustering of disturbances within cancer sites. Table 3 Estimates of effects of imaging and drug innovation on cancer mortality rate, controlling and not controlling for other factors
